Hosted on MSN6mon
Eli Lilly to buy Waltham-based drug developer for $3.2B
Drug manufacturer Eli Lilly is moving to buy Waltham-based biotech company Morphic Holding Inc. in a $3.2 billion deal. According to a statement, Lilly will pay $57 a share in cash for Morphic ...
pharmaphorum6mon
Lilly swoops on Morphic to claim IBD drug candidate
Eli Lilly has bolstered its inflammatory bowel disease (IBD) pipeline with a $3.2 billion bid to acquire Morphic and its mid-stage oral integrin therapy MORF-057. Lilly is launching a tender offer ...
Eli Lilly & Co: Buy Rating Backed by Promising Orfoglipron Trials and Strong Pharmaceutical Pipeline
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...